Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Emotional dysregulation in adult ADHD and response to atomoxetine.

Reimherr FW, Marchant BK, Strong RE, Hedges DW, Adler L, Spencer TJ, West SA, Soni P.

Biol Psychiatry. 2005 Jul 15;58(2):125-31.

PMID:
16038683
2.

Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis.

Robison RJ, Reimherr FW, Marchant BK, Faraone SV, Adler LA, West SA.

J Clin Psychiatry. 2008 Feb;69(2):213-21.

PMID:
18211131
3.

Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine.

Marchant BK, Reimherr FW, Halls C, Williams ED, Strong RE, Kondo D, Soni P, Robison RJ.

Atten Defic Hyperact Disord. 2011 Sep;3(3):237-44. doi: 10.1007/s12402-011-0054-2. Epub 2011 Mar 27.

PMID:
21442440
4.
5.

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T.

Depress Anxiety. 2009;26(3):212-21. doi: 10.1002/da.20549.

PMID:
19194995
6.

Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity.

Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J.

J Clin Psychiatry. 2006 Mar;67(3):415-20.

PMID:
16649828
7.

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D.

J Clin Psychopharmacol. 2009 Feb;29(1):44-50. doi: 10.1097/JCP.0b013e318192e4a0.

PMID:
19142107
8.

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ.

J Clin Psychiatry. 2002 Dec;63(12):1140-7.

PMID:
12523874
9.

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.

Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group.

Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28.

PMID:
19716683
10.

Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.

Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, Philipsen A, Herpertz S, Ammer R.

World J Biol Psychiatry. 2010 Aug;11(5):709-18. doi: 10.3109/15622971003624197.

PMID:
20353312
11.

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

Cheng JY, Chen RY, Ko JS, Ng EM.

Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Epub 2007 Jun 16.

PMID:
17572882
12.

Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.

Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, Saylor KE, Secnik K, Kelsey DK, Allen AJ.

J Clin Psychopharmacol. 2006 Dec;26(6):648-52.

PMID:
17110824
13.

Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.

Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR; Atomoxetine ADHD/SUD Study Group.

Drug Alcohol Depend. 2008 Jul 1;96(1-2):145-54. doi: 10.1016/j.drugalcdep.2008.02.009. Epub 2008 Apr 9.

PMID:
18403134
14.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
15.

Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.

Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM.

Clin Ther. 2012 Feb;34(2):363-73. doi: 10.1016/j.clinthera.2011.12.015. Epub 2012 Jan 27.

PMID:
22285724
17.

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.

Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, Witte MM.

Psychopharmacology (Berl). 2007 Jan;190(1):31-41. Epub 2006 Nov 9.

PMID:
17093981
18.

A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD.

Sobanski E, Sabljic D, Alm B, Baehr C, Dittmann RW, Skopp G, Strohbeck-Kuehner P.

Pharmacopsychiatry. 2012 May;45(3):100-7. doi: 10.1055/s-0031-1291319. Epub 2011 Dec 15.

PMID:
22174029
19.

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Simpson D, Plosker GL.

Drugs. 2004;64(2):205-22. Review.

PMID:
14717619
20.

Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.

Simpson D, Plosker GL.

CNS Drugs. 2004;18(6):397-401. Review.

PMID:
15089111

Supplemental Content

Support Center